MOLECULAR BASIS OF STEATOSIS AND STRUCTURAL CHANGES IN HEPATOCYTES DURING THE DISEASE.
DOI:
https://doi.org/10.5281/zenodo.20487850Keywords:
hepatic steatosis, fatty liver degeneration, hepatocellular lipid vacuolization, intrahepatic lipid accumulation, metabolic syndrome, insulin resistance, dyslipidemia, non-alcoholic fatty liver disease (NAFLD), steatohepatitis, liver fibrosisAbstract
This article explores the changes associated with fat accumulation in the liver, particularly the formation of large fat droplets within hepatocytes. In recent years, this condition has become increasingly common, often developing silently without noticeable symptoms in its early stages, which makes it especially relevant. The article focuses on the main causes of fatty liver disease, including unhealthy diet, sedentary lifestyle, and metabolic disorders. In addition, structural changes occurring in hepatocytes are explained through simple examples, making the topic easier to understand. The step-by-step progression of the process is also analyzed, from simple fat accumulation to inflammation and potentially severe complications. The main aim of the article is to highlight that this condition can remain unnoticed for a long time and may lead to serious consequences if not addressed in time. The importance of a healthy lifestyle and basic preventive measures is also briefly discussed.
References
1. Hepatic Steatosis: Etiology, Patterns, and Quantification. Idilman IS, Ozdeniz I, Karcaaltincaba M.Semin Ultrasound CT MR. 2016 Dec;37(6):501-510. doi: 10.1053/j.sult.2016.08.003. Epub 2016 Aug 12.PMID: 27986169 1. Hepatic Steatosis: Etiology, Patterns, and Quantification. Idilman IS, Ozdeniz I, Karcaaltincaba M.Semin Ultrasound CT MR. 2016 Dec;37(6):501-510. doi: 10.1053/j.sult.2016.08.003. Epub 2016 Aug 12.PMID: 27986169
2.[Nonalcoholic hepatic steatosis: a silent disease]. Aguilera-Méndez A.Rev Med Inst Mex Seguro Soc. 2019 Mar 15;56(6):544-549.PMID: 30889343
3.Hepatic steatosis: a benign disease or a silent killer. El-Zayadi AR.World J Gastroenterol. 2008 Jul 14;14(26):4120-6. doi: 10.3748/wjg.14.4120.PMID: 18636654
4.Microvesicular steatosis of the liver. Hautekeete ML, Degott C, Benhamou JP.Acta Clin Belg. 1990;45(5):311-26. doi: 10.1080/17843286.1990.11718105.PMID: 2177300
5.Cancer and hepatic steatosis. Paternostro R, Sieghart W, Trauner M, Pinter M.ESMO Open. 2021 Aug;6(4):100185. doi: 10.1016/j.esmoop.2021.100185. Epub 2021 Jun 15.PMID: 34139486
6.What's New in Hepatic Steatosis. Virarkar M, Szklaruk J, Jensen CT, Taggart MW, Bhosale P.Semin Ultrasound CT MR. 2021 Aug;42(4):405-415. doi: 10.1053/j.sult.2021.03.001. Epub 2021 Mar 9.PMID: 34130852
7.Amelioration of hepatic steatosis by dietary essential amino acid-induced ubiquitination. Zhang Y, Lin S, Peng J, Liang X, Yang Q, Bai X, Li Y, Li J, Dong W, Wang Y, Huang Y, Pei Y, Guo J, Zhao W, Zhang Z, Liu M, Zhu AJ.Mol Cell. 2022 Apr 21;82(8):1528-1542.e10. doi: 10.1016/j.molcel.2022.01.021. Epub 2022 Mar 3.PMID: 35245436
8.Fatty liver index (FLI): more than a marker of hepatic steatosis. Kaneva AM, Bojko ER.J Physiol Biochem. 2024 Feb;80(1):11-26. doi: 10.1007/s13105-023-00991-z. Epub 2023 Oct 25.PMID: 37875710
9.Systemic immune-inflammation index is associated with hepatic steatosis: Evidence from NHANES 2015-2018. Song Y, Guo W, Li Z, Guo D, Li Z, Li Y.Front Immunol. 2022 Nov 18;13:1058779. doi: 10.3389/fimmu.2022.1058779. eCollection 2022.PMID: 36466832
10.Meteorin-like alleviates hepatic steatosis by regulating hepatic triglyceride secretion and fatty acid oxidation. Song L, Huang Y, Liu L, Chang X, Hu L, Wang G, Xu L, Zhang T, Wang Y, Xiao Y, Yang H, Ran S, Shi Q, Wang T, Shi M, Zhou Y, Guo B.Cell Rep. 2025 Feb 25;44(2):115246. doi: 10.1016/j.celrep.2025.115246. Epub 2025 Feb 5.PMID: 39918960
11.Malonylation of Acetyl-CoA carboxylase 1 promotes hepatic steatosis and is attenuated by ketogenic diet in NAFLD. Cao H, Cai Q, Guo W, Su Q, Qin H, Wang T, Xian Y, Zeng L, Cai M, Guan H, Chen S, Liang H, Xu F.Cell Rep. 2023 Apr 25;42(4):112319. doi: 10.1016/j.celrep.2023.112319. Epub 2023 Mar 31.PMID: 37002924
12.Overexpression of NAG-1/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation.
13.Wang Y, Chen C, Chen J, Sang T, Peng H, Lin X, Zhao Q, Chen S, Eling T, Wang X.Redox Biol. 2022 Jun;52:102322. doi: 10.1016/j.redox.2022.102322. Epub 2022 Apr 27.PMID: 35504134
14.Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. Cell Mol Life Sci. 2019 Jan;76(1):99-128. doi: 10.1007/s00018-018-2947-0.




United Kingdom
Germany
France
Uzbekistan
Türkiye
Kazakhstan
Kyrgyzstan
Turkmenistan
Azerbaijan
India
Republic of Korea
Japan
United States of America
Kosovo
Italy
Spain
Poland
Netherlands
Belgium
Sweden
Norway
Finland
Denmark
Switzerland
Austria
Czech Republic
Hungary
Romania
Bulgaria
Greece
Portugal